Pular para o conteúdo principal
Ranking Invest

CDNA - CareDx, Inc

Segmento: HealthcareCareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
$ 406.75 Mi
Valor de Mercado
$ 2.60 Bi
Sobrepreço (AV)+539.0%
IVR
0.16A companhia vale 0,16 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.02O valuation alternativo equivale a -2% do valor de mercado da companhia.
MLL
-0.02O lucro líquido dos controladores em 16 trimestres equivale a -2% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 425.60 Mi

Dívida Líquida

-$ 373.64 Mi

L4T

$ 111.01 Mi

MM4T

21.03%

Indicadores Básicos

ROE

26.08%

Índices de Previsibilidade

Receita Líquida

D0.11

Lucro

F2.89

Margem

F2.96

Índices de Tendência

Receita Líquida

B9.56

Lucro

B6.22

Margem

B5.63

Índices de Endividamento

DIV/PAT

-0.88

DIV/L4T

-3.37

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.